NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

Is Cellebrite DI’s Latest Law Enforcement Partnerships Enough to Support Its Current Stock Valuation?

Curious if Cellebrite DI is a hidden bargain or just riding the current tech wave? Let’s unravel what really matters when it comes to the stock’s value. Cellebrite DI has seen a 19.8% surge over the past week, with its 1-year return sitting at 4.2% and a strong 299.4% climb over three years. However, it is down -14.8% year-to-date. In the past month, Cellebrite DI stock’s movement grabbed headlines after the company announced new partnerships with law enforcement agencies and rolled out...
OM:EPI A
OM:EPI AMachinery

Epiroc (OM:EPI A) Unveils Advanced Drill Bits: What the Latest Innovation Means for the Company's Valuation

Epiroc (OM:EPI A) has just introduced a new line of polycrystalline diamond drill bits, designed to deliver longer service life and superior wear resistance. This innovation targets efficiency gains, reduced downtime, and sustainability for mining and construction clients. See our latest analysis for Epiroc. Epiroc’s latest push into next-generation drilling tech comes at a time when its share price has seen some turbulence, with a sharp 8.2% decline over the past month but relative stability...
TSX:RGSI
TSX:RGSIOil and Gas

Rockpoint Gas Storage (TSX:RGSI): How Do Latest Earnings and Dividend Moves Impact Its Valuation?

Rockpoint Gas Storage (TSX:RGSI) just announced its latest quarterly earnings. The company reported higher revenue compared to last year, alongside the initiation of a quarterly dividend. Both of these developments could influence investor sentiment. See our latest analysis for Rockpoint Gas Storage. After a burst of interest around Rockpoint Gas Storage's latest earnings and dividend announcement, the shares have shown some momentum, climbing to $26.28 with a 1-week share price return of...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)

In early November 2025, UroGen Pharma reported third-quarter results, highlighted by preliminary Phase 3 data showing a 77.8% complete response for UGN-103 in treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and received FDA feedback supporting a potential New Drug Application for this therapy. This regulatory milestone not only validates UroGen’s clinical development approach but also indicates a clearer path toward new product approvals in the urothelial...